|
Neurofeedback for Treatment Resistant Depression
RECRUITINGN/ASponsored by Kymberly Young
Actively Recruiting
PhaseN/A
SponsorKymberly Young
Started2018-10-22
Est. completion2026-03-01
Eligibility
Age18 Years – 55 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT03428828
Summary
The purpose of this study is to determine the clinical efficacy of real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) training to increase the amygdala's response to positive autobiographical memories in patients with depression who are considered treatment-resistant
Eligibility
Age: 18 Years – 55 YearsHealthy volunteers accepted
Inclusion Criteria: * right-handed adults (ages 18 - 55) with a primary diagnosis of MDD according to diagnostic criteria DSM-5 for recurrent MDD who are currently depressed will be recruited to participate * must be able to give written informed consent prior to participation * must have fewer than 45% memories categorized as specific on the Autobiographical Memory Test * must have a SHAPS score \> 4, indicating the presence of anhedonia * unmedicated or stable on an SSRI antidepressant regime (at least 3 weeks to ensure symptoms are stable) * previously failed to respond to two previous SSRI medications according to either a medical record review or clinical interview during Visit 1 Exclusion Criteria: * have a clinically significant or unstable cardiovascular, pulmonary, endocrine, neurological, gastrointestinal illness or unstable medical disorder * met DSM-IV criteria for alcohol and/or substance dependence (other than nicotine) within 12 months prior to screening * have a history of traumatic brain injury * are unable to complete MRI scan due to claustrophobia or general MRI exclusions (e.g., shrapnel inside body) * are currently pregnant or breast feeding * are unable to complete questionnaires written in English * current (within 3 weeks of testing) use of any antipsychotics, anticonvulsants, stimulants, benzodiazepines, beta-blockers, or other medications (except SSRI antidepressants) likely to influence cerebral blood flow. Effective medications will not be discontinued for the purposes of the study. Inclusion of patients on stable antidepressant medications was decided in order to allow generalization towards a real world population * have a DSM-5 diagnosis of psychotic or organic mental disorder, bipolar I or II disorder or any past or current manic or hypomanic symptoms, autism, or a primary diagnosis of an anxiety disorder (though co-morbid anxiety will not be excluded) * have any eye problems or difficulties in corrected vision.
Conditions2
DepressionTreatment-resistant Depression
Locations1 site
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorKymberly Young
Started2018-10-22
Est. completion2026-03-01
Eligibility
Age18 Years – 55 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT03428828